Weekly Research Analysts’ Ratings Changes for ImmunityBio (IBRX)

A number of firms have modified their ratings and price targets on shares of ImmunityBio (NASDAQ: IBRX) recently:

• 2/23/2026 – ImmunityBio had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 2/23/2026 – ImmunityBio had its price target raised by HC Wainwright from $10.00 to $15.00. They now have a “buy” rating on the stock.
• 2/23/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
• 2/17/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
• 1/26/2026 – ImmunityBio had its price target raised by HC Wainwright from $8.00 to $10.00. They now have a “buy” rating on the stock.
• 1/22/2026 – ImmunityBio had its price target raised by BTIG Research from $6.00 to $9.00. They now have a “buy” rating on the stock.
• 1/20/2026 – ImmunityBio had its price target raised by Piper Sandler from $5.00 to $7.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
• 1/13/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
• 12/29/2025 – ImmunityBio had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Transactions at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. This trade represents a 5.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 426,967 shares of company stock valued at $3,565,662 over the last 90 days. 69.48% of the stock is owned by corporate insiders.

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.